A Phase 2B Study of RUC-4 in Subjects With ST-elevation MI
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2B prospective, blinded, randomized, placebo controlled, international
multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all
eligibility criteria. These subjects will be evaluated by highly trained paramedics who
transport the subjects to the participating hospitals in the Netherlands and the Czech
Republic. Hospitals and ambulance services with experience in ambulance studies will be
selected. Each subject will receive a single subcutaneous injection containing either RUC-4
Dose 1 (0.110 mg/kg) or RUC-4 Dose 2 (0.130 mg/kg) or placebo